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Immunogenicity of biologicals
Th  erapeutic monoclonal antibodies (TmAbs) that block 
tumor necrosis factor are powerful modalities in the 
treatment of various inﬂ   ammatory diseases, but both 
chimeric and human TmAbs can induce anti-TmAb anti-
bodies. Immunogenicity can change the pharmaco  kinetics 
of biological therapeutics, resulting in suboptimal 
therapeutic levels of the drug in patient serum. Th  e 
problem of immunogenicity against therapeutic anti-
bodies has been described since TmAbs have been on the 
market for the treatment of various inﬂ  ammatory 
diseases, and knowledge regarding anti-TmAb antibodies 
is increasing. Nevertheless, technical factors, 
standard  ization of the assays used to measure anti-TmAb 
anti  bodies, and the timing of the measurements make 
immunogenicity a complex subject to investigate. Several 
studies in various inﬂ  ammatory diseases demonstrate the 
presence of anti-TmAb antibodies [1]. Table 1 gives an 
overview of the reported frequency of anti-TmAb 
antibodies in inﬂ   ixi  mab (antibodies to inﬂ  iximab,  or 
ATIs) and in adali  mumab (anti-adalimumab antibodies, 
or AAAs) [2-22]. Th   e large variation in the percentages of 
anti-TmAb antibodies measured could be related to the 
diﬀ  erences in assays, duration of treatment, and the use 
of conco  mitant immunosuppressive treatment.
Relevance of anti-TmAb antibodies
In studies in which trough serum adalimumab or 
inﬂ  iximab concentrations were measured, the presence 
of anti-TmAb antibodies was associated with decreased 
serum drug levels and a diminished response [2,5-
7,10,11,13,14]. Furthermore, anti-TmAb antibodies in the 
presence of TmAb concentrations in patients serum lead 
to the formation of immune complexes [23]. Th  e 
continuous presence of immune complexes in the serum 
could lead to adverse events. Little is known about the 
safety of TmAb and anti-TmAb antibody immune com-
plexes. Th   e presence of ATIs and of immune complexes 
of various sizes might be associated with infusion-related 
hypersensitivity reactions [2,6,10,23,24]. In one study, 
higher concentrations of ATIs predicted a higher risk of 
infusion reactions [10]. Concomitant immunosuppressive 
therapy, in the form of methotrexate or azathioprine, was 
shown to be associated with a lower frequency of anti-
TmAb antibodies compared with TmAb mono  therapy in 
multiple studies [4,7,10-13,15,16,18,25]. Th  e adminis-
tration of concomitant immunosuppressive therapy 
could be an opportunity to bypass the detri  mental eﬀ  ect 
of immunogenicity on the eﬃ   cacy  of  biological 
therapeutics and possible immune complex-related 
adverse events. In rheumatoid arthritis (RA), biological 
therapeutics are preferably prescribed with concomitant 
disease-modifying antirheumatic drugs (DMARDs) since 
eﬀ   ectiveness is increased compared with monotherapy 
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© 2010 BioMed Central Ltd[26]. It is unclear whether this eﬀ   ect is related to a 
synergistic or an anti-immunogenic eﬀ   ect. However, in 
clinical practice, the decision to prescribe concomitant 
immunosuppressive treatment is deter  mined by many 
factors: adverse events or intolerance, patient’s preference, 
rheumatologist’s preference, eﬀ   ect ive ness  of  immuno-
uppressant monotherapy, and co  morbidity. Also, daily 
practice diﬀ  ers among inﬂ  am  matory diseases; for example, 
in RA, it is common to prescribe methotrexate together 
with biological treat  ment, but in Crohn disease, the 
number of patients receiving concomitant immuno-
modulators is lower [13]. In psoriasis, methotrexate treat-
ment is often discon  tinued before the start with biological 
treatment, and in ankylosing spondylitis, eﬀ  ective thera-
peutic options (DMARDs) are lacking [22,27]. Further-
more, there are no clear guidelines on prescribing 
concomitant immuno  suppressants.
Current knowledge
We performed a systematic PubMed search of articles on 
the subject of concomitant immunosuppressive therapy 
with TmAb treatment. Search terms were inﬂ  iximab, 
adalimumab, rheumatoid arthritis, ankylosing spondy-
litis, psoriatic arthritis, psoriasis, Crohn disease, juvenile 
idiopathic arthritis, juvenile rheumatoid arthritis, immuno-
genicity, antibodies, anti-adalimumab antibodies, anti-
inﬂ  iximab antibodies, methotrexate, MTX, and immuno-
modulators. Articles were selected if a full text was 
available and if the formation of antibodies against 
adalimumab/inﬂ   iximab and the possible eﬀ  ect  of 
immunomodulators on immunogenicity were described. 
CLMK and GMB performed the PubMed search and 
evaluated all of the articles.
Prospective studies
Almost 15 years ago, Maini and colleagues [4] investi-
gated whether methotrexate could reduce the immuno-
genicity of inﬂ  iximab.  Th  e authors postulated that, if 
added to inﬂ  iximab in a dosage of 7.5 mg weekly, metho-
trexate itself would not be eﬀ  ective and toxicity would be 
minimized, but it would have an additive beneﬁ  t  on 
decreasing immunogenicity, and toxicity would be 
minimized. Th  ey performed a 26-week, double-blind, 
placebo-controlled, multicenter trial in which 101 
patients with RA were randomly assigned to one of seven 
groups, receiving inﬂ   iximab at 1, 3, or 10  mg/kg or 
placebo with or without methotrexate 7.5 mg per week 
for 14 weeks. Th   e overall incidence of ATIs after 26 weeks 
was 17.4%. Th   e development of antibodies was inversely 
associated with the inﬂ  iximab dose: 53%, 21%, and 7% in 
patients receiving 1, 3, and 10  mg/kg monotherapy, 
respectively. Th   e use of conco  mitant methotrexate 
greatly diminished the appearance of ATIs, with 
incidence rates of 15%, 7%, and 0% at the three dose 
levels. Th  e enzyme immunoassay used to measure the 
presence of ATIs was fully described in the article. Th  e 
authors suggest that immunologic tolerance to inﬂ  iximab 
was induced by higher dosages of inﬂ  iximab, probably 
because of the maintenance of circulating levels of 
inﬂ  iximab, and that this tolerance was potentiated by the 
simultaneous administration of methotrexate at a dose of 
7.5 mg per week.
In a prospective proof-of-concept study in patients 
with Crohn disease, the concomitant use of immuno-
suppressive therapy was compared with inﬂ  iximab 
monotherapy in 174 patients [13]. In one study arm, 65 
patients used concomitant azathioprine 2 to 2.5 mg/kg; 
in a second arm, 50 patients used concomitant intra-
muscular or subcutaneous methotrexate 15 mg weekly; 
and in a third arm, 59 patients received inﬂ  iximab mono-
therapy. Measurements of ATIs were performed by 
Prometheus Laboratories (San Diego, CA, USA) before 
and 4 weeks after each infusion. Again, the concomitant 
use of immunosuppressive therapy was associated with a 
lower incidence of ATIs compared with patients with 
inﬂ  iximab monotherapy (46% versus 73%, P <0.001). Th  is 
diﬀ  erence was observed in both the methotrexate arm 
(44% ATIs, P = 0.002) and the azathioprine arm (48% 
ATIs,  P = 0.004). When trough inﬂ  iximab levels were 
stratiﬁ  ed according to the presence or absence of ATIs, 
patients with ATIs had lower inﬂ   iximab levels than 
patients without ATIs and these levels were even lower 
when patients were not taking concomitant immuno-
suppressive treatment. Th   ere was a trend toward 
Table 1. Frequency of reported antibodies to infl  iximab and adalimumab in various infl  ammatory diseases
Infl  ammatory disease  ATIs, percentage  AAAs, percentage  References
Rheumatoid arthritis  8-52  12-44  [2-9]
Crohn disease  14-75  2.6-17  [10-17]
Juvenile idiopathic arthritis  NA  17  [18]
Ankylosing spondylitis  29  31  [19,20]
Psoriatic arthritis  NA  18  [21]
Psoriasis NA  45  [22]
AAA, anti-adalimumab antibody; ATI, antibody to infl  iximab; NA, not applicable.
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with a shorter duration of response in patients not taking 
concomitant immunosuppressive treatment compared 
with patients taking azathioprine or methotrexate 
(P = 0.06). Strikingly, when no ATIs were present, the 
duration of response was not inﬂ  uenced  by 
immunosuppressive co-treatment. Th   is suggests that the 
anti-immunogenic eﬀ   ect was more important than a 
possible synergistic eﬀ  ect.
Descriptive studies
Besides these prospective studies, a number of obser  va-
tional cohort studies on the subject of immunogenicity 
and studies with immunogenicity as secondary objective 
describe the postulated eﬀ   ect of immunosuppressive 
agents on immunogenicity of TmAbs [4,7,10-13,15,  16, 
18,25]. Th   ese studies and the two studies described above 
are summarized in Table 2.
During a 28-week cohort study, AAAs were detected in 
21/121 of adalimumab-treated RA patients (17%) [7]. A 
radioimmunoassay designed by Sanquin (Amsterdam, 
Th  e Netherlands) was used to measure the AAAs. 
Patients receiving concomitant methotrexate (mean 
dosage of 19.4 mg per week) had a lower rate of antibody 
development than patients receiving adalimumab mono-
therapy (12% versus 38%). EULAR (European League 
Against Rheumatism) non-responders had AAAs signiﬁ  -
cantly more often than good responders did (34% versus 
5%, P = 0.032). AAA formation corresponded with lower 
serum adalimumab concentrations at 28-week follow-up.
One hundred thirty-three patients with juvenile 
idiopathic arthritis (JIA) were randomly assigned to 
receive adalimumab or placebo [18]. In total, 16% of the 
patients had at least one positive test for AAAs during 
the study. Five of 85 patients (6%) receiving methotrexate 
and 22 of 86 patients (26%) not receiving methotrexate 
developed AAAs. Th   e presence of AAAs did not lead to a 
greater rate of discontinuation of adalimumab and did 
not increase the incidence of serious adverse events. Th  e 
assay used to measure AAAs was not described.
In Crohn disease, an anti-immunogenic eﬀ  ect  of 
concomitant immunosuppressive therapy was shown in a 
cohort study of 125 patients [10]. Patients who were 
taking immunosuppressive agents had a lower incidence 
of ATIs (43%) and higher inﬂ  iximab concentrations than 
patients who were not taking immunosuppressive agents 
(75%,  P <0.01). Tests were performed by Prometheus 
Laboratories. Th  e incidence of infusion reactions was 
reduced and the duration of response increased in 
patients taking immunosuppressive agents. Th  ere was a 
negative relation between the ATI concentration and the 
duration of response to inﬂ  iximab (P <0.001).
In the ACCENT I (Crohn disease without ﬁ  stulas) and 
II (ﬁ   stulizing Crohn disease) trials, patients received 
inﬂ   iximab induction therapy followed by placebo or 
maintenance therapy for up to 54 weeks [11,12]. In the 
ACCENT I trial, 442 patients were assessed for the 
presence of ATIs. Fourteen percent of patients developed 
ATIs, and 46% had an inconclusive result. Six percent of 
the patients receiving concomitant steroids and immuno-
modulators, 17% of the patients receiving concomitant 
steroids alone, 10% of the patients receiving concomitant 
immunomodulators alone, and 18% using inﬂ  iximab 
monotherapy developed ATIs. Median inﬂ  iximab con-
cen  tration in patients positive for antibodies was lower 
than in patients who had negative or inconclusive results. 
In the ACCENT II trial (n = 306 patients), response rates 
were similar among patients with (32%) or without (31%) 
ATIs. In this study, antibody status and eﬃ   cacy  of 
inﬂ   iximab were not related. Four percent of patients 
receiving concomitant steroids and immunomodulators, 
13% of patients receiving concomitant steroids alone, 
11% of patients receiving concomitant immuno  modu-
lators alone, and 24% using inﬂ  iximab  monotherapy 
developed ATIs. In both trials, infusion reactions occur-
red more often among patients with ATIs than among 
those without ATIs. In the ACCENT I trial as well as in 
the ACCENT II trial, assays used for the measurement of 
ATIs were not described in the text.
Recently, 508 biological and immunomodulator-naive 
Crohn disease patients were randomly assigned to 
receive azathioprine 2.5 mg/kg, inﬂ  iximab 5 mg/kg, or 
combination therapy with azathioprine and inﬂ  iximab 
for up to 26 weeks [25]. At 30 weeks, ATIs were detected 
in 1/116 patients (0.9%) receiving combination therapy 
and in 15/103 patients (14.6%) receiving inﬂ  iximab alone. 
Median trough inﬂ   iximab serum concentrations were 
higher for patients receiving combination therapy com-
pared with patients receiving inﬂ  iximab  mono  therapy 
(1.6 versus 3.5 μg/mL, P <0.001). Th  e assay used to 
measure ATIs was not described.
A small study of 30 adalimumab-treated patients with 
Crohn disease assessed whether AAAs aﬀ  ect adalimumab 
treatment outcome [16]. Seventeen percent of patients 
developed AAAs. Th  e presence of AAAs was related to 
non-response to adalimumab (odds ratio 13.1, conﬁ  dence 
interval 1.7 to 99.2, P = 0.006). Of the 13 patients using 
concomitant medication (steroids or immunomodu-
lators), only one patient (7.7%) developed AAAs, whereas 
20% of patients without concomitant medication 
developed these antibodies. AAAs were detected with 
the radioimmunoassay developed by Landsteiner Labora-
tory Sanquin Research (Amsterdam, Th  e  Netherlands).
After induction therapy in the CLASSIC I trial [17], 
276 patients with Crohn disease enrolled in the CLASSIC 
II trial and received open-label adalimumab 40 mg at 
weeks 0 and 2 [15]. Patients who were in remission at 
weeks 0 and 4 (55) in CLASSIC I were randomly assigned 
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or placebo for 56 weeks. Patients not in remission 
enrolled in an open-label arm and received adalimumab 
40 mg every other week. In these four groups, 17% to 
33% of the patients were treated with concomitant 
immunosuppressive agents. Remission rates did not 
diﬀ  er between patients treated with or without conco-
mitant immunosuppressants. Blood samples were 
collected for 269 out of 276 patients. Seven patients 
(2.6%) developed AAAs. Eighty-four out of 269 patients 
received concomitant immunosuppressants and none of 
them was positive for AAAs. Out of the 185 patients who 
did not receive concomitant immunosuppressive agents, 
7 patients (3.8%) developed AAAs. Assays used for the 
measurement of AAAs were not described.
Unclear or no eff  ect shown
Besides the studies described above (in which a beneﬁ  cial 
eﬀ  ect of concomitant immunosuppressive therapy on the 
immunogenicity of TmAbs was described), a few studies 
show less or no eﬀ  ect of immunomodulators on immuno-
genicity. In an observational cohort study on adalimumab 
therapy for Crohn disease (n  =  168), concomitant 
immuno  modulator therapy at baseline did not aﬀ  ect 
treatment outcome, trough serum concentration, or the 
development of antibodies against adalimumab and had 
no negative impact on serious adverse events. Only time 
to dose escalation was longer in patients who were 
treated with immunomodulators [14].
In a study of 106 patients with RA, 40% of anti-
inﬂ   iximab antibody-positive patients were treated 
concomitantly with methotrexate and this frequency did 
not diﬀ  er signiﬁ  cantly from that of patients who were 
ATI-negative (50%). However, patients who were 
receiving methotrexate had antibody levels that were 
slightly lower than those of patients who were not 
receiving methotrexate [2]. In another study of 51 
patients with RA, only three patients were not taking 
concomitant immunosuppressants. Antibodies were 
detected in two of these three patients [6].
Perspective
Since the eﬀ  ect of methotrexate on the immunogenicity 
of inﬂ  iximab in patients with RA was described by Maini 
and colleagues [4] almost 15 years ago, there has been 
only one other prospective study on the eﬀ  ect  of 
concomitant medication on the immunogenicity of 
inﬂ  iximab. Both studies indicate a clear eﬀ  ect of metho-
trexate and azathioprine on the formation of ATIs in 
patients with RA or Crohn disease. Although no pros-
pective studies of adalimumab on this subject have been 
performed, other cohort studies describing the eﬀ  ect of 
immunomodulator co-treatment on the immuno  genicity 
of adalimumab show similar results. Th  erefore, we 
conclude that there appears to be a favorable eﬀ  ect of 
immunosuppressive co-treatment on the immuno-
genicity of adalimumab and inﬂ  iximab.
Few data are available on the occurrence of adverse 
events associated with concomitant immunosuppres-
sants, but even fewer data are available on the safety of 
anti-TmAb antibodies. Th   e lack of known clinical mani-
festations associated with anti-drug antibodies does not 
imply that the continuous stimulation of the immune 
system and the development of immune complexes are 
harmless.
Th   e occurrence of (serious) adverse events, or (S)AEs, 
did not increase when immunomodulators were added to 
TmAbs in Crohn disease and RA [28,29]. Only the 
Table 2. The eff  ect of methotrexate or azathioprine on the formation of antibodies against adalimumab or infl  iximab
        % AAAs   IS + % AAAs  IS − % AAAs    
Study  Disease  TmAbs  IS used  or ATIs  or ATIs  or ATIs  P value  Assay
Maini et al. [4]  RA  IFX  MTX  17.4%  0%-15%  7%-53%  NA  LoBuglio et al. [30]
Vermeire et al. [13]  Crohn  IFX  AZA  55%  46%  73%  P <0.001  Prometheus Laboratories 
      MTX          (San Diego, CA, USA)
Baert et al. [10]  Crohn  IFX  MTX  61%  43%  75%  P <0.01  Prometheus Laboratories
ACCENT I [11]  Crohn  IFX  MTX  14%  10%  18%  NA  NA
ACCENT II [12]  Crohn  IFX  MTX  32%  11%  24%  NA  NA
Colombel et al. [25]  Crohn  IFX  AZA  NA  0.9%  14.6%  NA  NA
Bartelds et al. [7]  RA  ADA  MTX  17%  12%  38%  NA  Sanquin (Amsterdam, The Netherlands)
Lovell et al. [18]  JIA  ADA  MTX  16%  6%  26%  NA  NA
West et al. [16]  Crohn  ADA  MTX  17%  7.7%  20%  NA  Sanquin
CLASSIC II [15]  Crohn  ADA  MTX  2.6%  0%  3.8%  NA  NA
AAA, anti-adalimumab antibody; ACCENT, A Crohn’s Disease Clinical Trial Evaluating Infi  ximab in a New Long-term Treatment Regimen in Patients With Fistulizing 
Crohn’s Disease; ADA, adalimumab; ATI, antibody to infl  iximab; AZA, azathioprine; CLASSIC, Clinical Assessment of Adalimumab Safety and Effi   cacy Studied as 
Induction Therapy in Crohn’s Disease; IFX, infl  iximab; IS, immunosuppressive treatment; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NA, not applicable; RA, 
rheumatoid arthritis; TmAb, therapeutic monoclonal antibody.
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in patients receiving immunomodulators (12.5%) com-
pared with patients not receiving concomitant immuno-
suppressants (22.0%) [28]. Of 4,879 patients treated with 
adalimumab, 5.3% using at least one concomitant 
DMARD reported an SAE versus 7.3% of the patients 
using adalimumab monotherapy. Th   is frequency did not 
diﬀ  er among various DMARDs [29].
Th   e mechanism behind the eﬀ  ect of immunosuppres-
sants on immunogenicity has not been elucidated. We 
hypothesize that by adding immuno  modulators to the 
TmAbs, the immune response will be suppressed, leading 
to a decrease in antibody formation. In other words, 
methotrexate or azathioprine could block the expansion 
of the immune reactive cells, whereby the formation of 
anti-TmAb antibodies is reduced in quantity.
Optimization of treatment response should be the 
main goal when prescribing costly biological thera-
peutics. Especially in those inﬂ   ammatory diseases in 
which it is not common to prescribe concomitant 
immuno  modulating therapy, great beneﬁ  ts in lowering 
the incidence of anti-TmAb antibodies could be achieved 
by the use of concomitant immunosuppressants, result-
ing in an increased portion of patients with therapeutic 
concentrations of TmAbs in their blood.
Th  e concomitant use of immunosuppressants has not 
been associated with a higher incidence of (S)AEs; 
however, to minimize the risk of toxicity/intolerance, the 
minimal suﬃ     cient dose of immunosuppressants to 
decrease the immunogenicity of TmAbs should be 
assessed. To facilitate an evidence-based consensus on 
prescribing concomitant immunosuppressive therapy in 
various inﬂ  ammatory diseases, a prospective, controlled, 
dose-ﬁ  nding trial is warranted.
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